Chemical Property of Escitalopram
Chemical Property:
- Appearance/Colour:white or white crystalline powder
- Vapor Pressure:8.04E-15mmHg at 25°C
- Boiling Point:428.3 °C at 760 mmHg
- PKA:9.57±0.28(Predicted)
- Flash Point:212.8 °C
- PSA：110.86000
- Density:1.18 g/cm3
- LogP:2.96858
- Storage Temp.:2-8°C
- Solubility.:Soluble in DMSO
- XLogP3:3.2
- Hydrogen Bond Donor Count:0
- Hydrogen Bond Acceptor Count:4
- Rotatable Bond Count:5
- Exact Mass:324.16379146
- Heavy Atom Count:24
- Complexity:466
- Purity/Quality:
-
99%, *data from raw suppliers
Escitalopram *data from reagent suppliers
Safty Information:
- Pictogram(s):
- Hazard Codes:
- MSDS Files:
-
SDS file from LookChem
Useful:
- Canonical SMILES:CN(C)CCCC1(C2=C(CO1)C=C(C=C2)C#N)C3=CC=C(C=C3)F
- Isomeric SMILES:CN(C)CCC[C@@]1(C2=C(CO1)C=C(C=C2)C#N)C3=CC=C(C=C3)F
- Recent ClinicalTrials:Vortioxetine in the Elderly vs. Selective Serotonin Reuptake Inhibitors (SSRIs): a Pragmatic Assessment
- Recent EU Clinical Trials:Investigation of SSRI induced neuroplastic changes in musicians using functional magnetic resonance imaging
- Recent NIPH Clinical Trials:The effect of Escitalopram on REM sleep behavior disorder
-
Uses
antidepressive;selective serotonin reuptake inhibitor (S)-Citalopram is an inhibitor of serotonin (5-HT) uptake. Antidepressant.
-
Clinical Use
SSRI antidepressant:Depressive illnessPanic and social anxiety disorder
-
Drug interactions
Potentially hazardous interactions with other drugsAnalgesics: increased risk of bleeding with aspirin
and NSAIDs; risk of CNS toxicity increased with
tramadol.Anti-arrhythmics: increased risk of ventricular
arrhythmias with amiodarone, disopyramide and
dronedarone - avoid.Antibacterials: increased risk of ventricular
arrhythmias with IV erythromycin, moxifloxacin,
pentamidine and telithromycin.Anticoagulants: effect of coumarins possibly
enhanced; possibly increased risk of bleeding with
dabigatran.Antidepressants: avoid concomitant use with MAOI,
increased risk of toxicity; increased risk of CNS
toxicity with moclobemide - avoid concomitant use;
avoid concomitant use with St John’s wort; possibly
enhanced serotonergic effects with dapoxetine
and duloxetine; can increase concentration of
tricyclics; increased agitation and nausea with
tryptophan; increased risk of CNS toxicity with
rasagiline; possible increased risk of convulsions with
vortioxetineAntiepileptics: convulsive threshold lowered.Antihistamines: increased risk of ventricular
arrhythmias with mizolastine - avoid.Antimalarials: avoid concomitant use with
artemether/lumefantrine and piperaquine with
artenimol; possible increased risk of ventricular
arrhythmias with chloroquine and quinine.Antipsychotics: possibly increased risk of ventricular
arrhythmias with haloperidol, phenothiazines and
pimozide - avoid.Antivirals: concentration possibly increased by
ritonavir.Beta-blockers: increased risk of ventricular
arrhythmias with sotalol - avoid.Dopaminergics: avoid with selegiline; increased risk
of CNS toxicity with rasagiline.5HT1
agonist: increased risk of CNS toxicity with
sumatriptan; possibly increased risk of serotonergic
effects with naratriptan.Linezolid: use with care, possibly increased risk of
side effects.Lithium: increased risk of CNS effectsMethylthioninium: risk of CNS toxicity - avoid if
possible.
